Jennifer Robinson
Investor Relations Contact en VERVE THERAPEUTICS, INC. .
Perfil
Jennifer Robinson is currently the Vice President of Investor Relations & Communications at Verve Therapeutics, Inc. Prior to her current position, she worked as the Senior Director of Investor Relations at Dyax Corp.
from 2014 to 2016, and as the Senior Director of Investor Relations at Ra Pharmaceuticals, Inc. and resTORbio, Inc. She also served as the Vice President of Investor Relations & Communications at Deciphera Pharmaceuticals, Inc. Ms. Robinson received her undergraduate degree from Dartmouth College.
Cargos activos de Jennifer Robinson
| Empresas | Cargo | Inicio |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Investor Relations Contact | - |
Antiguos cargos conocidos de Jennifer Robinson.
| Empresas | Cargo | Fin |
|---|---|---|
| DYAX CORP. | Investor Relations Contact | 01/04/2016 |
| RA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| DECIPHERA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| ADICET BIO, INC. | Investor Relations Contact | - |
Formación de Jennifer Robinson.
| Dartmouth College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jennifer Robinson
